Actuate Therapeutics (ACTU) announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The company intends to use the net proceeds from the proposed offering for working capital and general corporate purposes. Lucid Capital Markets is acting as sole book-running manager for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACTU:
- Actuate Therapeutics files $250M mixed securities shelf
- Actuate Therapeutics initiated with a Buy at B. Riley
- Actuate Therapeutics, Inc.: Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating
- Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial
- Actuate Therapeutics files to sell 1.33M shares of common stock for holders